Amedisys Company Profile (NASDAQ:AMED)

About Amedisys (AMED)

Amedisys logoAmedisys, Inc. is a healthcare services company. The Company's segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia. The Company's Home Health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The Hospice segment provides support for those who are dealing with a terminal illness. The Personal care segment provides patients with assistance with the essential activities of daily living.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Home Health Care
  • Sub-Industry: Health Care Services
  • Exchange: NASDAQ
  • Symbol: AMED
  • CUSIP: 02343610
Key Metrics:
  • Previous Close: $54.20
  • 50 Day Moving Average: $51.50
  • 200 Day Moving Average: $46.02
  • 52-Week Range: $34.58 - $55.16
  • Trailing P/E Ratio: 49.27
  • Foreward P/E Ratio: 22.97
  • P/E Growth: 1.22
  • Market Cap: $1.82B
  • Outstanding Shares: 33,607,000
  • Beta: 1.43
  • Net Margins: 2.93%
  • Return on Equity: 11.94%
  • Return on Assets: 7.17%
  • Debt-to-Equity Ratio: 0.20%
  • Current Ratio: 1.06%
  • Quick Ratio: 1.06%

Analyst Ratings

Consensus Ratings for Amedisys (NASDAQ:AMED) (?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $54.14 (0.11% downside)

Analysts' Ratings History for Amedisys (NASDAQ:AMED)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/28/2017Jefferies Group LLCSet Price TargetBuy$57.00LowView Rating Details
3/3/2017Oppenheimer Holdings Inc.Reiterated RatingOutperform$50.00 -> $59.00N/AView Rating Details
3/1/2017MizuhoBoost Price TargetNeutral -> Neutral$33.00 -> $50.00N/AView Rating Details
1/27/2017Benchmark Co.Initiated CoverageHold$50.00N/AView Rating Details
1/17/2017Craig HallumSet Price TargetBuy$60.00N/AView Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
6/16/2016StephensInitiated CoverageEqual Weight$55.00N/AView Rating Details
5/16/2016Robert W. BairdReiterated RatingHoldN/AView Rating Details
5/6/2016Royal Bank of CanadaBoost Price TargetSector Perform$41.00 -> $48.00N/AView Rating Details
1/11/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformN/AView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$42.00 -> $45.00N/AView Rating Details
6/9/2015Deutsche Bank AGUpgradeHold -> Buy$28.00 -> $41.00N/AView Rating Details
5/27/2015SunTrust Banks, Inc.UpgradeNeutral -> Buy$31.00 -> $36.00N/AView Rating Details
(Data available from 4/29/2015 forward)


Earnings History for Amedisys (NASDAQ:AMED)
Earnings by Quarter for Amedisys (NASDAQ:AMED)
Earnings History by Quarter for Amedisys (NASDAQ:AMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q4 2016$0.39$0.44$368.14 million$366.30 millionViewN/AView Earnings Details
11/3/2016Q3$0.36$0.36$361.08 million$361.60 millionViewListenView Earnings Details
8/2/2016Q2$0.42$0.42$353.07 million$360.00 millionViewListenView Earnings Details
5/3/2016Q1$0.33$0.33$337.07 million$348.80 millionViewListenView Earnings Details
3/8/2016Q415$0.35$0.40$322.67 million$338.37 millionViewListenView Earnings Details
11/5/2015Q315$0.34$0.34$312.22 million$326.50 millionViewListenView Earnings Details
7/29/2015Q215$0.33$0.43$307.11 million$314.20 millionViewListenView Earnings Details
4/29/2015Q115$0.20$0.30$300.17 million$301.60 millionViewListenView Earnings Details
3/4/2015Q414$0.27$0.27$301.62 million$300.50 millionViewListenView Earnings Details
10/29/2014Q314$0.17$0.28$299.26 million$300.30 millionViewListenView Earnings Details
7/30/2014Q214$0.17$0.25$298.90 million$305.00 millionViewListenView Earnings Details
5/8/2014Q114($0.06)($0.07)$301.89 million$298.74 millionViewListenView Earnings Details
3/12/2014Q413($0.01)($0.05)$295.02 million$303.50 millionViewListenView Earnings Details
11/12/2013Q313$0.13$0.06$314.30 million$301.64 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.10$0.06$328.02 million$313.10 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.18$0.13$361.41 million$339.20 millionViewListenView Earnings Details
3/12/2013Q4 2012$0.22$0.24$373.31 million$632.90 millionViewListenView Earnings Details
11/6/2012Q312$0.27$0.33$379.97 million$375.62 millionViewN/AView Earnings Details
8/7/2012$0.24$0.27ViewN/AView Earnings Details
5/8/2012$0.22$0.22ViewN/AView Earnings Details
2/28/2012$0.29$0.25ViewN/AView Earnings Details
11/1/2011$0.50$0.36ViewN/AView Earnings Details
8/2/2011$0.69$0.75ViewN/AView Earnings Details
4/26/2011$0.66$0.53ViewN/AView Earnings Details
2/22/2011$0.91$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amedisys (NASDAQ:AMED)
2017 EPS Consensus Estimate: $2.05
2018 EPS Consensus Estimate: $2.42
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.40$0.42$0.41
Q2 20173$0.48$0.55$0.51
Q3 20173$0.52$0.56$0.54
Q4 20173$0.58$0.62$0.60
Q1 20182$0.45$0.56$0.51
Q2 20182$0.58$0.60$0.59
Q3 20182$0.62$0.64$0.63
Q4 20182$0.69$0.69$0.69
(Data provided by Zacks Investment Research)


Dividend History for Amedisys (NASDAQ:AMED)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Amedisys (NASDAQ:AMED)
Insider Ownership Percentage: 2.80%
Institutional Ownership Percentage: 94.88%
Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)
Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/13/2016Bruce D PerkinsDirectorBuy1,000$50.21$50,210.00View SEC Filing  
5/11/2016Scott G GinnInsiderSell6,000$51.62$309,720.00View SEC Filing  
11/2/2015North Tide Capital, LlcMajor ShareholderSell277,720$39.79$11,050,478.80View SEC Filing  
10/28/2015North Tide Capital, LlcMajor ShareholderSell191,400$39.86$7,629,204.00View SEC Filing  
10/26/2015North Tide Capital, LlcMajor ShareholderSell56,400$39.32$2,217,648.00View SEC Filing  
8/18/2015Donald A WashburnDirectorSell20,000$45.51$910,200.00View SEC Filing  
3/13/2015Jeffrey D JeterInsiderSell11,264$27.02$304,353.28View SEC Filing  
3/13/2015Peter RicchiutiDirectorSell2,003$27.25$54,581.75View SEC Filing  
8/5/2014Jeffrey D JeterInsiderSell2,500$21.80$54,500.00View SEC Filing  
5/8/2014North Tide Capital, Llcmajor shareholderBuy500,000$13.90$6,950,000.00View SEC Filing  
5/1/2014North Tide Capital, Llcmajor shareholderBuy150,000$13.54$2,031,000.00View SEC Filing  
11/21/2013Kkr Asset Management Llcmajor shareholderBuy425,515$14.48$6,161,457.20View SEC Filing  
11/15/2013David BuceyGeneral CounselSell8,290$13.95$115,645.50View SEC Filing  
11/14/2013Kkr Asset Management Llcmajor shareholderBuy946,500$13.89$13,146,885.00View SEC Filing  
10/30/2013Kkr Asset Management LlcMajor ShareholderBuy29,615$15.94$472,063.10View SEC Filing  
10/22/2013Kkr Asset Management LlcMajor ShareholderBuy186,013$17.55$3,264,528.15View SEC Filing  
10/18/2013Kkr Asset Management LlcMajor ShareholderBuy12,652$17.95$227,103.40View SEC Filing  
7/3/2013Linda J HallDirectorSell1,721$10.65$18,328.65View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amedisys (NASDAQ:AMED)
Latest Headlines for Amedisys (NASDAQ:AMED)
DateHeadline logoJefferies Group LLC Analysts Give Amedisys Inc (AMED) a $57.00 Price Target - April 29 at 12:11 PM logoFavorable Press Coverage Likely to Impact Amedisys (AMED) Stock Price - April 27 at 2:36 PM logoETFs with exposure to Amedisys, Inc. : April 25, 2017 - April 25 at 3:29 PM logoAmedisys Announces First Quarter 2017 Earnings Release and Conference Call Date - April 24 at 3:33 PM logoSomewhat Positive Press Coverage Very Likely to Impact Amedisys (AMED) Stock Price - April 23 at 8:21 AM logoAmedisys Inc (AMED) Expected to Post Quarterly Sales of $370.03 Million - April 20 at 1:47 PM logoAmedisys (AMED) Receives News Impact Score of 0.19 - April 20 at 12:47 PM logoAmedisys Inc (AMED) Lowered to Hold at Zacks Investment Research - April 18 at 4:00 PM logoZacks: Analysts Expect Amedisys Inc (AMED) Will Announce Earnings of $0.41 Per Share - April 18 at 2:59 PM logoAmedisys Inc (AMED) Upgraded to Buy by Zacks Investment Research - April 17 at 7:15 PM logoAmedisys (AMED) Earns Daily Coverage Optimism Rating of -0.29 - April 17 at 11:44 AM logoSomewhat Positive Media Coverage Very Likely to Impact Amedisys (AMED) Share Price - April 14 at 4:22 PM logoAmedisys Inc (AMED) Sees Large Growth in Short Interest - April 10 at 8:07 AM logoAmedisys (AMED) Poised on Strong Home Health, Risks Remain - April 7 at 8:03 AM logoAmedisys Inc (AMED) Receives Average Rating of "Hold" from Brokerages - April 5 at 11:09 AM logoBlog Coverage Amedisys Acquires East Tennessee Personal Care Service to Expand its Operations in Tennessee - April 3 at 3:47 PM logoAmedisys to Buy East Tennessee to Expand in Personal Care - April 3 at 3:47 PM logoAmedisys Announces Definitive Agreement to Acquire East Tennessee Personal Care Service - April 1 at 10:00 AM logoEquities Analysts Issue Forecasts for Amedisys Inc's Q1 2018 Earnings (AMED) - March 22 at 10:46 AM logoAmedisys to Present at the 27th Annual Oppenheimer Healthcare Conference - GlobeNewswire (press release) - March 14 at 8:03 AM logoAmedisys to Present at the 27th Annual Oppenheimer Healthcare Conference - March 13 at 8:35 PM logoAmedisys Inc (AMED) Given Average Recommendation of “Hold” by Brokerages - March 9 at 12:21 PM logoAmedisys (AMED) Catches Eye: Stock Gains 6.2% in Session - March 2 at 8:45 PM logoAmedisys (AMED) Catches Eye: Stock Gains 6.2% in Session - Yahoo Finance - March 2 at 3:44 PM logoAMEDISYS Inc 2016 Q4 - Results - Earnings Call Slides - March 1 at 3:29 PM logo7:10 pm Amedisys beats by $0.05, reports revs in-line - March 1 at 3:29 PM logoAMEDISYS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - March 1 at 3:29 PM logoAmedisys Reports Fourth Quarter and Year End 2016 Financial Results - Yahoo Finance - March 1 at 8:13 AM logoAMEDISYS INC Files SEC form 10-K, Annual Report - March 1 at 8:13 AM logoAmedisys  beats by $0.05, misses on revenue - March 1 at 12:14 AM logoAMEDISYS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial S - February 28 at 8:36 PM logoAmedisys Reports Fourth Quarter and Year End 2016 Financial Results - February 28 at 7:27 PM logoAmedisys Announces Fourth Quarter Earnings Release and Conference Call Date - February 28 at 9:23 AM logoQ4 2016 Amedisys Inc Earnings Release - After Market Close - February 28 at 9:23 AM logoForm 4 AMEDISYS INC For: Feb 22 Filed by: Pernosky Lawrence R - February 26 at 10:30 AM logoForm 4 AMEDISYS INC For: Feb 22 Filed by: LABORDE RONALD A - February 25 at 8:27 PM logoForm 4 AMEDISYS INC For: Feb 22 Filed by: Pernosky Lawrence R - - February 25 at 3:26 PM logoForm 4 AMEDISYS INC For: Feb 22 Filed by: LABORDE RONALD A - - February 25 at 1:43 AM


Frequently Asked Questions for Amedisys (NASDAQ:AMED)

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) announced its quarterly earnings results on Tuesday, February, 28th. The company reported $0.44 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.39 by $0.05. The company earned $366.30 million during the quarter, compared to the consensus estimate of $368.14 million. Amedisys had a net margin of 2.93% and a return on equity of 11.94%. The firm's quarterly revenue was up 8.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.40 earnings per share.

When will Amedisys make its next earnings announcement?

Amedisys is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys issued an update on its third quarter earnings guidance on Thursday, October, 27th. The company provided EPS guidance of $0.35-0.37 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.44. The company issued revenue guidance of ~$362 million, compared to the consensus revenue estimate of $360.86 million.

Where is Amedisys' stock going? Where will Amedisys' stock price be in 2017?

9 brokerages have issued 12-month price objectives for Amedisys' stock. Their predictions range from $48.00 to $60.00. On average, they anticipate Amedisys' stock price to reach $54.14 in the next year.

What are analysts saying about Amedisys stock?

Here are some recent quotes from research analysts about Amedisys stock:

  • 1. According to Zacks Investment Research, "Over the last month, Amedisys has steadily traded above the Zacks categorized Medical-Outpnt/Hm Care industry. Market is particularly positive on the company’s consistent and stellar Home Health division’s performance with solid organic growth in Medicare and non-Medicare revenues. We are also upbeat about the company’s initiative for strategically fit merger and acquisition activities, the most recent deal being East Tennessee Personal Care Service. The company’s strong cash position further bolsters our confidence in the stock. However, CMS’ recently proposed Home Health rule in 2017 proved grossly unfavorable for Amedisys indicating gloomy scenario ahead. Also, Escalation in operating expenses and margin contractions continue to raise concern." (4/18/2017)
  • 2. Jefferies Group LLC analysts commented, "We are excited about AMED's 2017 outlook given our view that the company's Q4 performance (margin-driven earnings beat) foreshadows accelerating realization of benefits from its recently-completed IT rollout that should translate into strong earnings power and stock upside. Additionally, AMED's strong balance sheet and robust FCF, coupled with its $100MM EBITDA deal pipeline, should translate to an active year for accretive, upside-driving acquisitions." (3/1/2017)
  • 3. Mizuho analysts commented, "Bumps? What bumps? AMED produced 4Q16 SS home health admit growth, nice margin gains and 15% upside to our adj. EBITDA estimate. For '17E, AMED seems poised to realize $40+mm in actual cost savings, admit growth in HH and continued strong growth in hospice, enough to more than offset a $17 mm hit from HH pricing to achieve EBITDA growth of 28%+ in '17E. But the not-so-cheap stock price "knows" that even though we have no guidance yet and a brand new management team. So we reset our PT at $50 to reflect market re-rating, strong results and the prospect of the real, new AMED emerging in 2017." (3/1/2017)

Are investors shorting Amedisys?

Amedisys saw a increase in short interest in March. As of March 15th, there was short interest totalling 3,680,763 shares, an increase of 2.0% from the February 28th total of 3,608,198 shares. Based on an average daily trading volume, of 310,053 shares, the short-interest ratio is presently 11.9 days.

Who owns Amedisys stock?

Amedisys' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wells Fargo & Company MN (4.45%), Monarch Partners Asset Management LLC (0.52%), Nationwide Fund Advisors (0.38%), Kalmar Investments Inc. DE (0.25%), Russell Investments Group Ltd. (0.11%) and Bank of Montreal Can (0.10%). Company insiders that own Amedisys stock include Bruce D Perkins, Donald A Washburn, North Tide Capital, Llc and Scott G Ginn.

Who sold Amedisys stock? Who is selling Amedisys stock?

Amedisys' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Kalmar Investments Inc. DE, Jennison Associates LLC, Nationwide Fund Advisors, Boston Advisors LLC, Profund Advisors LLC, Capstone Asset Management Co. and Nisa Investment Advisors LLC.

Who bought Amedisys stock? Who is buying Amedisys stock?

Amedisys' stock was acquired by a variety of institutional investors in the last quarter, including Monarch Partners Asset Management LLC, Bank of Montreal Can, Russell Investments Group Ltd., First Midwest Bank Trust Division, Louisiana State Employees Retirement System and State of Alaska Department of Revenue.

How do I buy Amedisys stock?

Shares of Amedisys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Amedisys stock cost?

One share of Amedisys stock can currently be purchased for approximately $54.20.

Amedisys (AMED) Chart for Saturday, April, 29, 2017

This page was last updated on 4/29/2017 by Staff